At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 125 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks for 'prognostic factors' — things that may help predict how the illness develops over time — in people with advanced mycosis fungoides (MF) or Sézary syndrome (SS), stages IIB to IVB. The conditions listed for the study are mycosis fungoides and non-Hodgkin's lymphoma. The study is sponsored by Stanford University.
Who can take part
- You have been told you have advanced-stage mycosis fungoides (MF) or Sézary syndrome (SS) — stage IIB to IVB — within 6 months of first coming to the study centre.
- Your care is expected to happen at the study centre, or together with the doctor who referred you, so that follow-up information about you is available.
Who may not be able to
- You were first diagnosed with early-stage MF or SS (stage IA to IIA) before it moved on to an advanced stage.
- You were diagnosed with advanced MF or SS more than 6 months before first coming to the study centre.
- You are a new patient coming for a one-off consultation only.
What taking part involves
- • Not stated — ask the trial team
Time commitment: Visits and duration are not stated — ask the trial team; taking part involves your follow-up information being available to the study team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- Not specified
- Who
- All
- Number of participants
- 2,000
- Started
- 2016-10
- Last checked
- 2025-10
Plain English Summary
What is this study?
- • Testing a new treatment for mycosis fungoides
- • Clinical study - 2,000 participants
- • The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome
Who can take part?
- • Adults
- • Diagnosed with mycosis fungoides
Where?
- • Birmingham - University Hospitals Birmingham
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: Not specified
- Who can join: All genders
What the study is looking for
- ✓Inclusion Criteria
- ✓Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center
- ✓Patients that are expected to have care administered at the participating center or jointly with referring...
- ✓Exclusion Criteria
- ✓Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage
See the full criteria
Where Is This Study? (1 UK site)
University Hospitals Birmingham
Birmingham, United Kingdom
How to Get in Touch
Tatiana Neal
Sponsor contactCONTACT